华大智造拟收购三箭齐发及华大序风100%股权 构建“短读长+长读长+空间组学”全覆盖技术生态

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to acquire 100% equity of Shenzhen Hualong Sanjian Qifa Technology Co., Ltd. and Hangzhou Hualong Xufeng Technology Co., Ltd. for a total price of 366 million yuan, aiming to enhance its technological ecosystem in gene sequencing and life science tools [1][2]. Group 1: Acquisition Details - The acquisition will allow the company to gain control over the two target companies and integrate their core technologies, including spatial genomics and nanopore sequencing, into its existing short-read sequencing platform [1]. - The transaction has been approved by the company's board and will be submitted for shareholder approval [1]. Group 2: Technological Integration - The integration of short-read, long-read, and spatial genomics technologies will enhance the company's product matrix and support its transformation from a leading gene sequencing instrument provider to a comprehensive life science tool creator [1][2]. - The spatial genomics technology from Sanjian Qifa is at the international leading level in resolution and field of view, applicable in fields like brain science and regenerative medicine, and is highly compatible with the existing DNBSEQ sequencing platform [2]. Group 3: Financial Impact and Future Growth - Both target companies are currently in the R&D phase and have not yet achieved profitability, which may impact the company's operating profit in the short term; however, they possess strong innovation and commercialization potential, likely becoming new growth engines for the company [2]. - The companies are expected to achieve profitability by 2026 and 2028, respectively, contributing to the company's overall competitiveness and profitability in the long term [2]. Group 4: Strategic Positioning - The acquisition aligns with the company's strategic layout and enhances its independent innovation capabilities, reinforcing its leading position in the gene sequencing field [2]. - The company is also focusing on the "AI + gene sequencing" sector and advancing its laboratory automation and AI-driven software tools, establishing a robust foundation for its intelligent ecosystem [3].